Teleflex Incorporated

NYSE:TFX

Medical - Instruments & Supplies

Healthcare
$165.85 +0.83%

+$1.04 today

Market cap
$6.58B
Beta
0.82
P/E (TTM)
-5.5
EPS (TTM)
-$22.79
Dividend yield
1.08%
52W Low $100.18High $139.67

Volume 1.16M

Average 0.80M

TFX Debt Repayment

Cash used to repay borrowings during the period.

Teleflex IncorporatedNYSE: TFX

Debt Repayment · Q2 FY2026 · quarter ended Jun 2026

Debt repayment turns positive

Q2 FY2026 debt repayment was $200.25M, compared with -$9.05M a year earlier. Trailing-twelve-month debt repayment was $912.41M.

Context

  • Debt repayment amounted to 49.3% of revenue in FY2025, up 44.0 pp from a year earlier.
  • Debt repayment increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly debt repayment holds near $200.25M or moves back toward the trailing-twelve-month quarterly average of $228.1M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$200.25M+893.1% QoQ
Last fiscal yearDec 2025
$982.04M+708.1% YoY
LTMJun 2026
$912.41M+410.9% YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2312.7%——
1 year+708.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Debt Repayment history

USD · from the cash flow

Latest · FY2025
982.04M USD
Year-over-year change
+708.1%

Debt Repayment vs competitors

How TFX compares with its peers on the latest reported figures

  • Peers report in different currencies, so debt repayment is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +410.9% is the 3rd highest of 7, against a peer median of +24.3%.
  • Debt repayment amounts to 35.1% of revenue for TFX, versus a peer median of 2.0%.
TFX Competitors
Debt Repayment for TFX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALKSAlkermes plcLTM Sep 2026$3.01B USD+1140.8%—171.8%
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026$1.18B USD+714.2%—260.7%
TFXTeleflex IncorporatedLTM Jun 2026$912.41M USD+410.9%—35.1%
TGTXTG Therapeutics, Inc.LTM Sep 2026$490.06M USD——54.6%
BLCOBausch + Lomb CorporationLTM Jun 2026$141.75M USD-51.5%-53.4%2.7%
STVNStevanato Group S.p.A.LTM Jun 2026€24.54M EUR-74.4%—2.0%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$1.61M USD-208.1%—0.2%
PCVXVaxcyte, Inc.LTM Jun 2026$0 USD———
KRYSKrystal Biotech, Inc.LTM Jun 2026$0 USD——0.0%
MMSIMerit Medical Systems, Inc.LTM Sep 2026$0 USD+100.0%—0.0%
CRSPCRISPR Therapeutics AGLTM Sep 2026$0 USD——0.0%
Peer median (excluding TFX) —+24.3%-53.4%2.0%

Competitors are the stored peer set for TFX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income485.37M363.14M356.33M69.68M58.53M
Depreciation & Amortization237.36M230.59M242.12M274.6M177.74M
Deferred Income Tax(110.24M)(13.01M)(13.05M)0(100.97M)
Stock-Based Compensation22.94M27.22M31.47M31.35M0
Change in Working Capital127.35M(239.96M)(111.77M)(1.82M)(81.09M)
Accounts Receivables(600K)(38.46M)(15.76M)(27.95M)(85.53M)
Inventory(11.14M)(110.69M)(41.07M)1.72M84.04M
Accounts Payables94.02M(24.79M)(31.26M)9.67M(8.28M)
Other Working Capital45.06M(66.03M)(23.68M)14.74M(71.31M)
Other Non-Cash Items(111.36M)(25.84M)5.55M261.94M286.46M
Operating Cash Flow651.42M342.14M510.64M635.74M340.68M
Capital Expenditures(71.62M)(79.19M)(91.44M)(126.43M)(95.24M)
Acquisitions (Net)220.32M(186M)(588.92M)(120K)(825.15M)
Purchases of Investments(18.42M)(22.3M)(11.3M)(7.3M)(5M)
Sales of Investments7.3M7.3M7.3M7.3M0
Other Investing Activities19.15M22.24M63.13M27.2M76.19M
Investing Cash Flow156.74M(257.94M)(621.23M)(99.36M)(849.19M)
Debt Repayment(634.5M)(145.45M)101.25M(161.5M)982.04M
Common Stock Issued11.1M4.31M000
Common Stock Repurchased0(4.31M)0(200M)(300M)
Dividends Paid(63.65M)(63.79M)(63.9M)(63.54M)(60.27M)
Other Financing Activities(28.77M)(8.27M)1.19M3.12M(10.23M)
Financing Cash Flow(715.82M)(217.51M)38.54M(421.93M)611.54M
Effect of Forex Changes(23.13M)(19.74M)2.86M(9.65M)(29.35M)
Net Change in Cash69.2M(153.05M)(69.19M)104.8M73.68M
Free Cash Flow579.8M262.95M419.2M509.31M245.44M

Teleflex Incorporated

NYSE:TFX

Intrinsic Alpha fair value

Locked

Current Price

$165.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.